Loading quotes...

Forecast

Buy	5
Hold	14
Sell	1

News Go to news feed

Barclays cuts Novartis price target to 125 francs, rating remains 'Equal Weight'

The British investment bank Barclays has cut its price target for Novartis from 130 to 125 francs, while the 'Equal Weight' rating remains unchanged. The reason is that Remibrutinib fell slightly short of expectations on two key efficacy aspects in the MS trial; the stock is likely to disappoint in the short term. » More on finanzen.net
Novartis reports positive phase‑III data on remibrutinib in relapsing multiple sclerosis

Novartis says the regulatory phase‑III trials Remodel‑1 and Remodel‑2 with the oral BTK inhibitor remibrutinib showed a significantly greater reduction in relapse rate compared with teriflunomide. Specifically, the company reported roughly one relapse over 13 years. The safety profile was described as robust, with no liver safety signals observed. The data were presented at the MSToronto2026 conference. » More on finanzen.net
Novartis expands US approval for Rhapsido to include symptomatic dermographism

The FDA has approved Novartis’s Rhapsido (Remibrutinib) for the treatment of symptomatic dermographism in the US, extending its indication beyond chronic spontaneous urticaria. In the phase‑III RemIND study, twice as many adults treated with Rhapsido achieved complete resolution of hives by week 12 compared with placebo. Rhapsido is now the only medicine indicated for these two most common forms of chronic hives. Novartis shares fell as much as about 1.07 percent to 118.74 francs on the SIX. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, NOVARTIS has already paid €4.09 in dividends. The last payout was in March.

Financials

In the last quarter, NOVARTIS had revenue of €12.4B and net profit of €2.81B

(EUR)	June 2026	YoY
Revenue	12.4B	1.46%
Gross profit	9.24B	5.44%
Net profit	2.81B	18.04%
EBITDA	5.13B	0.50%

Fundamentals

Metric	Value
Market capitalization	€263.18B
Number of shares	1.9B
52-week high/low	€143.53 - €104.99
Dividend yield	2.98%
Dividends TTM	€4.09
Beta	0.47
P/E ratio	23.57
PEG ratio	-5.25
P/B ratio	7.10
P/S ratio	5.39

Company profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Name	NOVARTIS
CEO	Vasant Narasimhan
Headquarters	Basel, bs Switzerland
Website	novartis.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	08/02/2018
Employees	75,267